![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, June 08, 2011 10:02:18 AM
Director, Division of Medical Imaging and Radiopharmaceutical Drug Products, U.S. Food and Drug Administration
I am the Division Director in the Division of Medical Imaging and Radiopharmaceutical products, which report to the Office of New Drugs within CDER/FDA. My division is responsible for the review and approval of diagnostic imaging drugs and radiolabeled therapeutic oncologic drugs. In my capacity, I direct a staff of 34 professionals involved in the various disciplines of the review of INDs, BLAs, and NDAs.
In my prior 10+ years with FDA, I have served as a medical officer, Team Leader, Branch Chief, and as the Acting Deputy Division Director of the biologics oncology branch/division within CBER and CDER. In these positions, I served as the medical scientific Chief of the Oncology Branch/Division and as a CBER/CDER expert on medical diagnostic imaging and therapeutic radiopharmaceutical oncologic biologics and drugs. In addition, I served as a CBER/CDER expert on the review of radiographic imaging submissions in support of various licensure submissions throughout CBER/CDER.
During my experience in the Oncology Branch/Division, I have performed, directed, and coordinated the work of the professional staff within the Oncology Branch to complete the IND, BLA and NDA clinical, pharmtox, product, and project management reviews as required of the staff. I was responsible for recommending approval and/or rejection of Biologic License Applications (BLAs), supplements, Notices of Claimed Investigational Exception [INDs] and other regulatory actions pertaining to investigational biologic drugs.
Prior to coming to FDA, I was in the private clinical practice of diagnostic/therapeutic Nuclear Medicine and Pathology for 16 years. In the course of my private practice, I participated in various clinical trials with diagnostic and therapeutic biologic products.
http://www.biomarkers.org/staff/mills.html
Recent NAVB News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/21/2023 08:32:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 11:26:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 04:49:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 09:55:52 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 10/23/2023 05:56:24 PM
- Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock • Business Wire • 10/06/2023 01:01:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/05/2023 08:21:49 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/15/2023 07:42:35 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/11/2023 04:15:30 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM